Skip to main content

spartalizumab

Generic: Spartalizumab

spartalizumab: 4 clinical trials tracked.

spartalizumab evidence translation

What we can confirm

4 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about spartalizumab, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trials (4)

An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

NCT05201066·Phase 2·NVS
Active, not recruiting

Primary endpoint: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

Interventionalopen33 enrolledStarted 2023-02Completion 2028-0224 sites · Australia, Brazil, Canada, China…Novartis Pharmaceuticals

A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations

NCT04895748·Phase 1·NVS
Terminated

Primary endpoint: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

Interventionalopen40 targetStarted 2021-11Completion 2026-0211 sites · Czechia, France, Italy, Japan…Novartis Pharmaceuticals

An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments

NCT04058756·Phase 1·NVS
Active, not recruiting

Primary endpoint: Frequency and nature of AE and SAE by subject

Interventionalopen120 enrolledStarted 2019-10Completion 2030-0448 sites · Belgium, Canada, China, Czechia…Novartis Pharmaceuticals

A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)

NCT04028245·Early Phase 1
Completed

Primary endpoint: Percentage of subjects who proceed to radical nephrectomy

Interventionalopen17 enrolledStarted 2019-08Completion 2026-031 site · United StatesColumbia University